Chemotherapy for Non-Small Cell Lung Cancer
Author Information
Author(s): M.H. Cullen, R. Joshi, A.D. Chetiyawardana, C.M. Woodroffe
Primary Institution: Queen Elizabeth Hospital, Birmingham
Hypothesis
Can the combination of mitomycin, ifosfamide, and cis-platin improve treatment outcomes in patients with inoperable non-small cell lung cancer?
Conclusion
The combination of mitomycin, ifosfamide, and cis-platin is effective in treating non-small cell lung cancer, with a significant response rate and manageable toxicity.
Supporting Evidence
- 30 patients achieved partial remission (45%) and 7 achieved complete remission (11%).
- The overall response rate was 56%.
- The median response duration was 8.75 months.
- The median survival for the whole group was 9.2 months.
Takeaway
This study tested a new combination of cancer drugs on patients with lung cancer, and many of them got better.
Methodology
A phase 2 study was conducted with 74 patients receiving a regimen of mitomycin, ifosfamide, and cis-platin, with assessments of response, toxicity, and survival.
Limitations
The study was limited to patients with inoperable non-small cell lung cancer and did not include a control group.
Participant Demographics
74 patients, 65 male and 9 female, aged 27-70 (median 61), with varying performance status.
Statistical Information
P-Value
0.0003
Confidence Interval
95% CI 44%-68%
Statistical Significance
p=0.002
Want to read the original?
Access the complete publication on the publisher's website